Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerationsBenjamin Dehay, Wassilios G. Meissner, Miquel Vila et al.|The Lancet Neurology|2015Cited by 508
The γ-Secretase Inhibitor N-[N-(3,5-Difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl Ester Reduces Aβ Levels in Vivo in Plasma and Cerebrospinal Fluid in Young (Plaque-Free) and Aged (Plaque-Bearing) Tg2576 MiceThomas A. Lanz, Kalpana Merchant, Carol S. Himes et al.|Journal of Pharmacology and Experimental Therapeutics|2003Cited by 147